Back to Report Store Home

Global Neurodegenerative Diseases Drugs Market to 2023 – MS Set to Dominate with Tecfidera and Ocrevus, as Disease-Modifying Pipeline Therapies for Alzheimer’s Disease and SMA Show Clinical and Commercial Potential

  • Published: Feb-2018
  • Report Code: GBIHC469MR
  • Report Format: pdf

Description

List of Tables

Table 1: Neurodegenerative Disease Drugs Market, Symptoms of AD, PD, MS, HD and ALS, 2017

Table 2: Neurodegenerative Disease Drugs Market, Global, Epidemiology, 2017

Table 3: Neurodegenerative Disease Drugs Market, Global, Alzheimer’s Disease Neurological Tests and Disease Staging, 2017

Table 4: Neurodegenerative Disease Drugs Market, Global, Parkinson’s Disease UPRDS Scale, 2017

Table 5: Neurodegenerative Disease Drugs Market, Global, Parkinson’s Disease Revised Hoehn and Yahr Scale, 2017

Table 6: Neurodegenerative Disease Drugs Market, Global, Huntington’s Disease Unified Huntington’s Disease Rating Scale, 2017

Table 7: Neurodegenerative Disease Drugs Market, Global, Huntington’s Disease Shoulson and Fahn Staging Scale, 2017

Table 8: Neurodegenerative Disease Drugs Market, Global, Amyotrophic Lateral Sclerosis King's Method, 2017

Table 9: Neurodegenerative Disease Drugs Market, Global, Treatment Options Available for Parkinson’s Disease, 2017

Table 10: Neurodegenerative Disease Drugs Market, Global, Approved Indications for Copaxone, 2018

Table 11: Neurodegenerative Disease Drugs Market, Global, Approved Indications for Tecfidera, 2018

Table 12: Neurodegenerative Disease Drugs Market, Global, Approved Indications for Gilenya, 2018

Table 13: Neurodegenerative Disease Drugs Market, Global, Approved Indications for Avonex, 2018

Table 14: Neurodegenerative Disease Drugs Market, Global, Approved Indications for Tysabri, 2018

Table 15: Neurodegenerative Disease Drugs Market, Global, Approved Indications for Ocrevus, 2018

Table 16: Neurodegenerative Disease Drugs Market, Global, Approved Indications for Namenda/Ebixa/Axura/Abixa/Memary, 2018

Table 17: Neurodegenerative Disease Drugs Market, Global, Approved Indications for Aricept, 2018

Table 18: Neurodegenerative Disease Drugs Market, Global, Approved Indications for Azilect, 2018

Table 19: Neurodegenerative Disease Drugs Market, Global, Approved Indications for Neupro, 2018

Table 20: Neurodegenerative Disease Drugs Market, Global, Approved Indications for Radicut 2018

Table 21: Neurodegenerative Disease Drugs Market, Global, Approved Indications for Xenazine, 2018

Table 22: Neurodegenerative Disease Drugs Market, Global, Approved Indications for Spinraza, 2018

Table 23: Neurodegenerative Disease Drugs Market, Global, Usage of Generics Across Key Indications, 2018

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards